PMID- 34078765
OWN - NLM
STAT- MEDLINE
DCOM- 20220307
LR  - 20220307
IS  - 1880-3873 (Electronic)
IS  - 1340-3478 (Print)
IS  - 1340-3478 (Linking)
VI  - 28
IP  - 12
DP  - 2021 Dec 1
TI  - Evidence-Experience Gap and Future Perspective on the Treatment of Peripheral 
      Artery Disease.
PG  - 1251-1259
LID - 10.5551/jat.RV17058 [doi]
AB  - Peripheral artery disease (PAD) is a systemic disease associated with impaired 
      limb function, poor quality of life, and increased cardiovascular morbidity. Its 
      incidence has been dramatically increasing over years because of the emergence of 
      an aging society and the increase in the number of patients with atherosclerotic 
      risk factors. The clustering of these risk factors promotes disease development, 
      reportedly leading to the differential location of atherosclerotic lesions in 
      lower extremity arteries. The clinical presentations of PAD include intermittent 
      claudication and chronic limb-threatening ischemia (CLTI). PAD is associated with 
      a high risk of mortality and morbidity from both cardiovascular and limb events. 
      The therapeutic goals for patients with PAD include 1) relief from PAD-related 
      limb symptoms, 2) the prevention of new-onset and the development and recurrence 
      of PAD, and 3) the prevention of concomitant adverse events due to coronary 
      artery disease (CAD) and cerebrovascular disease (CVD). There are several types 
      of antithrombotic agents, and their main role in patients with PAD is to reduce 
      systemic events mainly including cardiovascular and lower extremity-related 
      events. Currently, the efficacy of direct oral anticoagulant (DOAC) is also 
      suggested by recent clinical trials. Although endovascular therapy (EVT) has been 
      a first-line revascularization strategy for symptomatic PAD, whether clinical 
      outcomes after EVT are comparable to those after surgical bypass therapy remains 
      inconclusive.
FAU - Iida, Osamu
AU  - Iida O
AD  - Cardiovascular Center, Kansai Rosai Hospital.
FAU - Takahara, Mitsuyoshi
AU  - Takahara M
AD  - Department of Diabetes Care Medicine, Osaka University Graduate School of 
      Medicine.
FAU - Mano, Toshiaki
AU  - Mano T
AD  - Cardiovascular Center, Kansai Rosai Hospital.
LA  - eng
PT  - Journal Article
DEP - 20210602
PL  - Japan
TA  - J Atheroscler Thromb
JT  - Journal of atherosclerosis and thrombosis
JID - 9506298
RN  - 0 (Fibrinolytic Agents)
SB  - IM
MH  - Angioplasty/methods
MH  - Chronic Limb-Threatening Ischemia/*prevention & control
MH  - Endovascular Procedures/methods
MH  - Fibrinolytic Agents/pharmacology
MH  - Heart Disease Risk Factors
MH  - Humans
MH  - Japan/epidemiology
MH  - *Peripheral Arterial Disease/epidemiology/psychology/therapy
MH  - Preventive Health Services
MH  - *Quality of Life
MH  - Severity of Illness Index
PMC - PMC8629708
OTO - NOTNLM
OT  - Chronic limb-threatening ischemia
OT  - Endovasular therapy
OT  - Peripheral artery disease
EDAT- 2021/06/04 06:00
MHDA- 2022/03/08 06:00
PMCR- 2021/12/01
CRDT- 2021/06/03 05:53
PHST- 2021/06/04 06:00 [pubmed]
PHST- 2022/03/08 06:00 [medline]
PHST- 2021/06/03 05:53 [entrez]
PHST- 2021/12/01 00:00 [pmc-release]
AID - DN/JST.JSTAGE/jat/RV17058 [pii]
AID - 10.5551/jat.RV17058 [doi]
PST - ppublish
SO  - J Atheroscler Thromb. 2021 Dec 1;28(12):1251-1259. doi: 10.5551/jat.RV17058. Epub 
      2021 Jun 2.